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Abstract: The aim of this study was to determine the response to an oral glucose tolerance test (OGTT)
in adult males with Becker muscular dystrophy (BMD) and Duchenne muscular dystrophy (DMD),
and to investigate whether body composition contributes to any variance in the glucose response.
Twenty-eight adult males with dystrophinopathy (BMD, n = 13; DMD, n = 15) and 12 non-dystrophic
controls, ingested 75 g oral anhydrous glucose solution. Fingertip capillary samples were assessed
for glucose at 30-min intervals over 2-h post glucose ingestion. Fat free mass relative to body mass
(FFM/BM) and body fat (BF%) was assessed using bioelectrical impedance. Vastus lateralis muscle
anatomical cross sectional area (VL ACSA) was measured using B-mode ultrasonography. Blood
glucose was higher in MD groups than control at 60, 90 and 120 min post ingestion of glucose.
Compared to controls, FFM/BM and VL ACSA were lower in MD groups compared to controls (p
< 0.001). Glucose tolerance values at 120 min were correlated with FFM/BM and BF% in the BMD
group only. Our results suggest that glucose tolerance is impaired following OGTT in adult males
with BMD and DMD. It is recommended that adults with BMD and DMD undertake routine glucose
tolerance assessments to allow early detection of impaired glucose tolerance.
Keywords: Duchenne muscular dystrophy; Becker muscular dystrophy; diabetes; oral glucose
tolerance test; body composition; muscle size
1. Introduction
Muscular dystrophy (MD) represents an umbrella term encompassing a group of myogenic
disorders of varying degrees of severity. These conditions each present with specific genetic
origins resulting in defects or absences within proteins of the dystrophin-sarcoglycan complex [1].
Both Duchenne (DMD) and Becker (BMD) muscular dystrophy share an identical genetic locus of
impairment (Xp21) and subsequently a similar anatomical distribution of musculoskeletal weakness [2].
Each of these dystrophinopathies are characterised by either absent or reduced expression of the
cytoskeletal protein dystrophin, resulting in progressive muscle degeneration with similar anatomical
distribution but varied severity [2–4]. DMD, characterised by non-functioning dystrophin, is the
most severe dystrophinopathy, with an estimated incidence of 3 in 100,000 boys [5,6]. BMD involves
partially functioning dystrophin, and is therefore a milder yet more variable form of dystrophinopathy,
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with an incidence of 2 in 100,000 male births [5,6]. The nuances of diagnosis and the variability of the
genetic defects of BMD and DMD are covered in detail elsewhere [7,8].
Although the presentation of clinical features such as atrophy and weakness is well described
in children and teenagers with DMD, the presentation of comparative data from adults with
dystrophinopathies and adults without MD remains limited [9–12]. With improved juvenile support
in DMD, mortality has improved [13,14]; with the potential increase in adult lifespan, the study of
co-morbidities associated with adults living with dystrophinopathies is essential. Recently we have
produced daily calorific guidelines for adults with BMD [11], and through analysis of body composition
and muscle mass it was apparent that broader dietary advice would be beneficial within this population.
It is known from the study of other clinical conditions associated with a decline in muscle mass, that
more than just functional impairments occur. For example, a higher fat mass and lower skeletal muscle
mass is associated with insulin resistance in musculoskeletal ageing [15] and is associated with a risk
of pre-diabetes/impaired glucose tolerance (IGT) within the general population [16]. An increased
prevalence of risk factors for the development of diabetes is understandable given that skeletal muscle
is essential as a glucose reservoir and as a target for insulin [17].
Despite previous reports of glucose tolerance and insulin resistance in children with BMD and
DMD, at present there is no description of the blood glucose response to an oral glucose tolerance test
(OGTT) in adults with DMD and BMD. Clinical guidelines for children with DMD suggest glucose
assessment should be “considered” [8], potentially because children with DMD do not consistently
show IGT [18–20]. It is likely that the progressive nature of DMD plays a role in this observation,
as non-ambulatory teenagers with DMD show impaired glucose tolerance in response to OGTT,
compared to children with DMD who were still ambulatory [19]. Furthermore, despite children with
DMD presenting with normal OGTT, fasted hyperinsulinemia is known to be associated with a high
body fat percentage in children with both BMD and DMD [21]; we have previously reported higher
body fat percentage in adults with DMD and BMD [11,22]. Despite the progressive nature of the
condition and the increasing adult lifespan, there are no reports of the blood glucose response to an
OGTT in adults with dystrophinopathies. In addition, given the association between body composition
(low skeletal muscle mass and high percentage body fat) and impaired glucose tolerance, it is currently
not known whether body composition may contribute to any difference in the blood glucose response
in adults with dystrophinopathies.
The aim of the present investigation was therefore twofold: (1) to investigate the response to an
OGTT in adults with BMD and DMD compared to controls without MD; and (2) to determine whether
alterations in body composition contributes to any variance in the glucose tolerance response in MD. It
is hypothesised that people with MD will display an impaired response to oral glucose ingestion as a
result of lower skeletal muscle mass and higher body fat percentage.
2. Materials and Methods
2.1. Participants
Twenty-eight men diagnosed with DMD (n = 15; age 24.6 ± 4.3 years, age range 19–34 years,
height 1.69 ± 0.07 m, mass 71.5 ± 13.8 kg) or BMD (n = 13; age 43.7 ± 7.3 years, age range 33–55 years,
height 1.76 ± 0.07 m, mass 96.5 ± 20.6 kg) and twelve healthy adult male controls (age 27.1 ± 7.4
years, age range 21–49 years, height 1.80 ± 0.08 m, mass 79.7 ± 11.9 kg) volunteered to participate in
this study. Four of the participants with BMD were ambulatory (able to walk with or without an aid),
nine were non-ambulatory (relied on the use of a wheelchair) and all participants with DMD were
non-ambulatory. In the DMD group 6 out of the 15 (40%) participants reported to be currently taking
corticosteroids (Prednisolone, n = 5; Deflazacort, n = 1, and have done so for over 10 years) and an
additional participant reported previous use. Control participants were adult males who were low to
moderately physically active based on current physical activity levels determined by the bone specific
physical activity questionnaire (5.3 ± 3.0). Control participants were unrelated to the DMD and BMD
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participants, were otherwise healthy and reported as having no family history of diabetes. Due to
the difference in age associated with presentation of the conditions, the participants could not be
age-matched between groups, but glucose tolerance is not reported to be affected across the age-range
used in this current study (19–55 years) [23]. All participants provided written informed consent
before taking part in the study, which was approved by the local Ethics Committee of Manchester
Metropolitan University. All procedures complied with the World Medical Association Declaration of
Helsinki [24].
2.2. Procedures
All participants attended two testing sessions on separate days; the MD group were tested at
The Neuromuscular Centre (Winsford, UK) and the control group were tested at the Manchester
Metropolitan University. Aside from measures of mass and stature, all participants were tested using
the same equipment. Visit 1 consisted of anthropometric and Bioelectrical Impedance measurements,
followed by an ultrasound scan of the vastus lateralis muscle. Visit 2 was used to assess the glucose
response to an OGTT. Participants attended both sessions in a fasted state.
2.3. Anthropometric Measurements
Stature and mass were measured using a wall-mounted stadiometer and digital scales in the
control group. In the MD group, height was calculated as point to point (index finger, elbow, shoulder
and across midline) span. In order to account for the known discrepancy between standing height and
arm span measures, a correction was applied consistent with regression data from adult Caucasian
males, the known error for making this correction is 3.5% [25]. MD participant height is presented
as this corrected value. Participants in the MD group were weighed in a digital seated scales system
(6875, Detecto, Webb City, MO, USA). The weight of shoes, splints, slings etc. were subtracted from the
gross weight post weighing. Body mass index (BMI), a primary risk factor for type 2 diabetes in the
general population [26,27], was calculated as body mass/height2.
2.4. Bioelectrical Impedance
Body composition measurements were calculated using Bioelectrical Impedance Analysis (BIA)
(Body STAT, 1500); all participants were measured once while seated and were at least two-hours
postprandial, having completed no exercise in the previous 12 h. Two proximal electrodes were placed
between the styloid process of the right ulna and radius and between the medial and lateral malleoli
of the right ankle. Two distal electrodes were placed on dorsal surfaces of metacarpals and metatarsals.
Values of fat mass (kg), body fat%, fat free mass (FFM) and relative FFM (FFM relative to body mass
(FFM/body mass)) were recorded for each participant. BIA has been shown to be valid and reliable in
comparison to DEXA, with a Pearson Correlation Coefficient of r = 0.99 in adults of healthy weight,
and r = 0.78 in an overweight population [28,29]. BIA has been recommended to assess nutritional
status of people with DMD [30], and has previously been shown to be valid when assessing in a seated
vs. a supine posture (between −2.3 and 2.4% difference between supine and seated measures using
BIA) [31].
2.5. Vastus Lateralis Anatomical cross Sectional Area
Anatomical Cross Sectional Area (ACSA) of the Vastus Lateralis (VL) muscle was measured
using real-time B-Mode ultrasonography. Resting ultrasound scans were taken with the participant
in a seated position. A series of transverse plane scans (width of probe, 7.5-MHz linear array probe,
MyLabTM Twice, Esaote, Cambridge, UK) were digitally recorded at the level of 50% of the VL muscle
length. VL length was measured from origin to insertion point, determined via an ultrasound scan in
the sagittal plane. Care was taken to ensure minimal pressure was applied to the VL during scanning
to avoid compression of the muscle. Strips of echo-absorptive tape (Transpore, 3M, St. Paul, MN, USA)
were placed longitudinally from the medial to lateral border of the muscle, at approximately 3 cm
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intervals. These strips of tape were used as echo-absorptive markers that project a shadow onto the
ultrasound image to provide a positional reference into the scanned structures. Individual images
each consisting of two reference markers were collected using capturing software (Adobe Premier
Elements, version 10, Adobe Systems, San Jose, CA, USA). The shadows from the echo-absorptive
markers allowed the images to be aligned along with the contour of the muscle, and the entire VL
ACSA to be recreated in a single image (Graphic Image Manipulation Program, GIMP Development).
The ACSA was then measured using digitising software (ImageJ 1.45, National Institutes of Health,
Bethesda, MD, USA). This method of ultrasound to measure ACSA has previously been reported as a
valid (Intraclass correlation = 0.998, and 1.7% mean error) and reliable (Intraclass correlation = 0.999)
measure in comparison to MRI [32].
2.6. Oral Glucose Tolerance Test
Consistent with the guidelines of the American Diabetes Association [33], after a 12-h overnight
fast, participants ingested a commercially available glucose solution (Rapilose® OGTT Solution, Penlan
Healthcare Ltd., Tunbridge Wells, UK), delivering the equivalent of 75 g of anhydrous glucose [33].
Fingertip blood samples were obtained 10 min prior to glucose ingestion and then 30, 60, 90 and 120
min post ingestion. Glucose levels were measured using a hand held blood glucose meter (OneTouch
Select® Plus, Lifescan Europe, Zug, Switzerland; coefficient of variation (CV) = 2.52%) [34]. The OGTT
was chosen, as the sensitivity of alternative approaches (e.g., HbA1C and fasted glucose tolerance
testing) are in question, particularly when screening for pre-diabetic conditions.
2.7. Physical Activity Questionnaires
Participants completed a bone specific physical activity questionnaire (BPAQ) [35]. The BPAQ
data was analysed using freeware developed by Weeks and Beck, and is presented as the “Total”
BPAQ, a combination of current and past physical activity [35]. Although not specifically designed
for measurements in individuals with disability, the BPAQ questionnaire has previously been used
in MD, is sensitive to the loss of ambulation in adults with dystrophinopathy and shows significant
correlations with disability specific health questionnaires, such as the PASIPD [10,11,36]. Participants
with MD also completed a disability specific physical activity questionnaire (PASIPD—Physical
Activity Score for Individuals with Physical Disabilities) [36]. This includes a lower activity threshold
and has subsequently been validated as a reliable outcome measure for physical activity in people
with disability [37].
2.8. Statistics
IBM SPSS Statistics 23 software was used to analyse the data. All data are presented as mean ± SD.
Age, relative FFM, BPAQ and PASIPD violated the parametric assumption of normal distribution
(Shapiro-Wilk test, p < 0.05), all other variables were normally distributed. All variables showed
homogeneity of variance (Levene’s test, p > 0.05) except for BMI, fat mass (kg), BPAQ and glucose
area under the curve (AUC). Differences between the three groups (DMD, BMD and controls) were
analysed using a one-way between groups ANOVA with Bonferroni corrected post hoc pairwise
comparisons for homogenous values and Dunnett’s T3 corrected post hoc pairwise comparisons for
non-homogenous variables. A three-way repeated measures ANOVA, with Bonferroni corrected post
hoc pairwise comparisons, was used to compare between groups differences in absolute OGTT values
at each time point. Variables that violated normal distribution were compared between groups using
the Kruskal Wallis test, with post-hoc Mann-Whitney U pairwise LSD (least significant difference)
comparisons, where appropriate.
Spearman’s correlations were carried out to highlight any relationships between specific variables.
Statistically significant differences and/or associations were accepted at α ≤ 0.05. Study power (β)
and effect size (pε2) are also reported.
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3. Results
3.1. Anthropometry and Body Composition
Participant characteristics and anthropometric measurements are displayed in Table 1. Age, body
mass and BMI were higher in the BMD group than the DMD (p < 0.001, p = 0.001 and p = 0.035,
respectively) and control groups (p < 0.001, p = 0.03 and p = 0.014, respectively); there was no difference
in age, body mass or BMI between the DMD and control group. The DMD group had lower height
than the BMD and control groups (p = 0.02 and p = 0.001, respectively), with no difference between
the BMD and control groups. Fat mass was higher in the BMD group than the DMD (p = 0.04) and
control groups (p = 0.001), and fat mass was higher in the DMD group compared to control (p = 0.005).
Body fat% was lower in the control group compared to the MD groups (p < 0.001). FFM was lower
in the DMD group compared to the BMD and control groups (p = 0.03 and p < 0.001, respectively).
Relative FFM (FFM relative to body mass (FFM/Body mass)), was lower in the BMD and DMD group
compared to controls (p < 0.001) with no difference between MD groups. VL ACSA was bigger in the
control group compared to the BMD and DMD groups (Table 1, p < 0.001).
Table 1. Participant characteristics and anthropometric measurements from adult males with (DMD
and BMD) and without (Control) muscular dystrophy (MD).
Control DMD BMD
N 12 15 13
Ambulatory 12 0 4
Current corticosteroid use (n) 0 6 0
Age (Years) 27.1 ± 7.4 24.6 ± 4.3 43.7 ± 7.3 *,#
Height (m) 1.80 ± 0.08 1.68 ± 0.07 *,# 1.76 ± 0.07
Body Mass (Kg) 79.7 ± 11.9 71.5 ± 13.8 96.5 ± 20.6 *,#
BMI (Kg/m2) 24.6 ± 2.5 25.2 ± 4.1 31.1 ± 6.7 *,#
Fat Mass (Kg) 13.9 ± 6.4 22.6 ± 6.2 * 36.9 ± 17.6 *,#
Body Fat% 16.4 ± 5.5 31.3 ± 3.8 * 35.4 ± 8.2 *
FFM (Kg) 65.7 ± 7.4 48.9 ± 8.6 *,# 59.5 ± 13.4
Relative FFM (%) 83.1 ± 5.5 68.7 ± 3.8 * 62.9 ± 12.7 *
VL ACSA (cm2) 32.2 ± 8.6 16.3 ± 9.5 * 16.9 ± 6.9 *
n with IGT 0 8 6
PASIPD - 7.2 ± 7.1 12.9 ± 7.8
BPAQ 49.7 ± 48.0 5.9 ± 8.2 * 10.1 ± 10.2 *
Data are presented as mean ± SD. BMI, body mass index; FFM, fat free mass; VL ACSA, vastus lateralis anatomical
cross sectional area; IGT, impaired glucose tolerance; PASIPD, Physical Activity Score for Individuals with Physical
Disabilities; BPAQ, bone specific physical activity score. PASIPD scores are omitted for the control group, as
the questionnaire is specific for persons with disability. * denotes a significant difference from control (p < 0.05).
# denotes a significant difference between Becker muscular dystrophy (BMD) and Duchenne muscular dystrophy
(DMD) (p < 0.05).
3.2. Oral Glucose Tolerance Test
There was a significant effect of time (p < 0.001; pε2 = 0.557; β = 1.000) and a significant time x
group interaction (p < 0.001; pε2 = 0.223; β = 0.979) on the blood glucose response (absolute values
for each time point) to oral glucose ingestion (Figure 1). Blood glucose values were higher in the DMD
and BMD groups compared to controls at 60, 90 and 120 min (p < 0.05, Figure 1), with no difference
between DMD and BMD.
Peak blood glucose values were significantly higher in the BMD group compared to controls
(10.9 ± 1.7 mmol/L and 8.8 ± 1.0 mmol/L, respectively; p = 0.003), with no difference between DMD
(9.9 ± 1.6 mmol/L) and either group. The AUC for the blood glucose values was higher in the DMD
and BMD groups compared to controls (973 ± 144 mmol/L/120 min, 1073 ± 154 mmol/L/120 min
and 815 ± 51 mmol/L/120 min, respectively; p < 0.05).
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Figure 1. Blood glucose response to oral glucose intake. Blood glucose response to oral glucose intake 
in people with muscular dystrophy (MD) (Duchenne MD (DMD) dashed line, n = 15; Becker MD 
(BMD) dotted line, n = 13) and controls (solid line, n = 12). * denotes a significant difference between 
MD groups and controls (p < 0.05). 
3.3. Physical Activity Questionnaires 
Total BPAQ scores were significantly lower in the DMD and BMD groups compared to controls 
(Table 1, p < 0.001). PASIPD scores were not significantly different between groups (Table 1). 
3.4. Correlations 
Blood glucose 120 min post glucose ingestion and Glucose AUC were not correlated with any 
anthropometric measures (Table 2) in the DMD and control groups. Glucose 120 min post glucose 
ingestion correlated with body fat% and relative FFM in the BMD group (0.554, p = 0.049 and −0.557, 
p = 0.048, respectively). Physical activity scores from the BPAQ questionnaire correlated with Glucose 
AUC in the DMD group (0.713, p = 0.003). PASIPD scores were not found to correlate with any of the 
glucose tolerance values. Despite age being significantly higher in the BMD group than the DMD and 
control groups, age was not correlated with glucose tolerance values in any group (0.084, p = 0.78; 
0.090, p = 0.75 and 0.007, p = 0.98, respectively). 
Table 2. Correlation analysis between anthropometric measurements, and markers of glucose uptake 
in males with (DMD and BMD) and without (Control) muscular dystrophy. 
 Glucose 120 min Glucose AUC 
 Control DMD BMD Control DMD BMD 
Body Mass 0.228 0.105 0.318 0.189 0.087 −0.107 
BMI 0.193 0.086 0.394 0.305 0.046 0.017 
Fat Mass 0.350 0.209 0.463 0.049 0.173 0.132 
Body Fat% 0.322 0.148 0.554 * −0.238 0.199 0.217 
FFM 0.063 0.118 −0.268 0.224 0.041 −0.286 
Relative FFM −0.434 −0.148 −0.557 * 0.028 −0.199 −0.203 
VL ACSA 0.434 −0.032 0.168 −0.224 0.279 −0.269 
Figure 1. Blood glucose response to oral glucose intake. Blood glucose response to oral glucose intake
in people with muscular dystrophy (MD) (Duchenne D (D D) dashed line, n = 15; Becker MD
(BMD) dotted line, n = 13) and controls (solid line, n = 12). * denotes a significant difference between
MD groups and controls (p < 0.05).
3.3. Physical Activity Questionnaires
Total BPAQ scores were significantly lower in the D D and B D groups compared to controls
(Table 1, p < 0.001). PASIPD scores were not significantly different bet een groups (Table 1).
3.4. Correlations
Blood glucose 120 min post glucose ingestio a l cose AUC were not correlated with any
anthrop metric measures (Table 2) in the DMD an l s. Glucose 120 min post glucose
ingestion correlated with body fat% and relative FF i t r p (0. 54, p = .049 and −0.557,
p = 0.048, respectively). Physical activity sc t BP questio naire correlated with Glucose
AUC in the DMD group (0.713, p = 0.0 3). SI s r s ere not found to correlate with any of the
glucose tolerance values. Despite age being significantly higher in the BMD group than the DMD and
control groups, age was not correlated with glucose tolerance values in any group (0.084, p = 0.78;
0.090, p = 0.75 and 0.007, p = 0.98, respectively).
Table 2. Correlation analysis between anthropometric measurements, and markers of glucose uptake
in males with (DMD and BMD) and without (Control) muscular dystrophy.
Glucose 120 min Glucose AUC
Control DMD BMD Control DMD BMD
Body Mass 0.228 0.105 0.318 0.189 0.087 − . 07
BMI 0.193 0.086 0.394 0.305 0.046 0.017
Fat Mass 0.350 0.209 0.463 0.049 0.173 0.132
Body Fat% 0.322 0.148 0.554 * −0.238 0.199 0.217
FFM 0.063 0.118 −0.268 0.224 0.041 −0.286
Relative
FFM −0.434 −0.148 −0.557 * 0.028 −0.199 −0.203
VL ACSA 0.434 −0.032 0.168 −0.224 0.279 −0.269
Data are presented as Spearman correlation coefficients. BMI, body mass index; FFM, fat free mass; VL ACSA,
vastus lateralis anatomical cross sectional area. * denotes a significant correlation (p < 0.05).
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4. Discussion
The main findings from the present study show impaired glucose tolerance following oral glucose
ingestion in adult males with Becker and Duchenne MD. Our data show a significantly greater AUC
for the blood glucose response to oral glucose ingestion in adults with DMD and BMD compared to
controls. The blood glucose values two hours post glucose ingestion show that 53% of the DMD group,
46% of the BMD group and 0% of the control group met the ADA’s criteria for IGT (>7.8 mmol/L).
Two of the DMD group met the ADA’s criteria for type II diabetes (>11.1 mmol/L). Our findings
may highlight a potentially hidden problem of impaired glucose tolerance in the adults with BMD
and DMD.
There are a number of potential mechanisms that can contribute to impaired glucose tolerance; we
had originally hypothesised that lean mass or leg muscle area may be a factor. An association between
relative FFM and blood glucose and between body fat percentage and blood glucose 2 h post OGTT
was observed in the BMD group. As no other associations were observed between any anthropometric
measure and glucose tolerance, the muscle reservoir hypothesis of glucose impairment [15,38] may not
fully explain the impaired glucose tolerance in this population. It is possible that our observation of no
relationship between VL ACSA or FFM and oral glucose tolerance, was due to the fact that what we
have measured in terms of skeletal muscle mass may in fact overestimate the ‘true’ muscle contractile
area in DMD and BMD participants due to the increased presence of intramuscular fat and connective
tissue. Although alternative techniques exist for the assessment of contractile area in DMD and BMD
these are usually in children, or more ambulant individuals [39–43]. The practicalities of scanning
adults with DMD and non-ambulatory BMD with associated contractures and lack of mobility render
this technique impossible with higher numbers of participants.
Although not reporting glucose tolerance data, previous observations in children with DMD and
BMD aged 4–17 years show impaired insulin resistance, particularly in those with higher BMI and body
fat [21]. A lower Insulin receptor affinity in children with DMD [18], particularly in erythrocytes [19], is
likely to contribute to IGT observed in adults with BMD and DMD in the present study. Corticosteroids,
often used in children with DMD [44], impair insulin-mediated glucose uptake by directly interfering
with components of the insulin signalling cascade, such as glycogen synthase kinase-3, glycogen
synthase and GLUT4 translocation [45]. In children with DMD, it is likely that the presentation of
IGT could be linked to corticosteroids. Despite steroid-induced diabetes mellitus being reported in
adults with other neurological conditions [46], in the present study IGT was no more prevalent in
those using corticosteroids than non-users (2/6 currently taking corticosteroids had IGT). As only two
participants of those classified as IGT, are currently taking corticosteroids, it would seem that the acute
corticosteroid use is not a primary factor in the present BMD and DMD participants.
The discrepancy of significant IGT in ours compared to previous DMD data, that showed no
significant glucose intolerance [19], can be attributed to the age of our participants (range 19–55
years) and the progressive nature of the condition. A distinction was previously made in the work
of Freidenberg and Olefsky [19] such that, impaired glucose tolerance was reported only in those
non-ambulatory participants (aged 14.7 ± 3.7 years), compared to the ambulatory participants (aged
8.9± 3.4 years) who showed no evidence of glucose intolerance. This would suggest condition severity
plays a role in glucose tolerance impairments when comparing children to adults with DMD. It should
be noted however, that the glucose tolerance impairments were similar between the ambulatory and
non-ambulatory BMD participants, and between DMD and BMD participants in the present study.
This similarity likely suggests that despite body composition being associated with glucose tolerance
in BMD (consistent with non-MD previously [15,16]), the impairment is likely to relate to the insulin
resistance identified above.
The prevalence of type 2 diabetes mellitus is rapidly increasing worldwide with known lifestyle
aetiology being diet, obesity and physical inactivity [47–49]. The combination of a western diet
(characterised by a high consumption of processed food, high-fat dairy products, sweets and desserts)
with a low level of physical activity or obesity has been associated with a particularly high risk for
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type 2 diabetes [50]. BPAQ scores of physical activity levels were significantly lower in the MD groups
than controls. Although not significantly correlated with glucose tolerance values, the lower level of
physical activity and higher body fat percentage could be contributing factors to IGT in the current
study. At present, we do not know whether diet has contributed to the observation of IGT in adults
with DMD and BMD, but acknowledge that lifestyle factors could contribute. Further research is
necessary to determine whether lifestyle, diet or the condition itself (or a combination of these factors)
contributes to the observed IGT in the present BMD and DMD participants.
As mentioned above, previous observations from BMD and DMD, have shown no evidence of
abnormal glucose tolerance that would lead to the classification of type 2 diabetes (a blood glucose
level 2 h post OGTT of >200 mg/dL or >11.1 mmol/L) [18–20]. Based on 2 h glucose response, 2 of our
15 DMD participants would be classified as having type 2 diabetes, with 8 of our 15 DMD and 6 of
our 13 BMD participants being classified as having IGT. There are a number of implications regarding
these observations in terms of contraindications and management of unregulated glucose intolerance;
it is well established that there are numerous cardiovascular, renal and neurological complications
associated with microvascular impairments secondary to type 2 diabetes [51].
Regardless of the potential mechanisms that may contribute to the impaired glucose tolerance
reported in the present study, the blood glucose levels at 120 min and greater glucose AUC has
shown that adult males with dystrophinopathies are at risk of developing type 2 diabetes as their
condition progresses with age. As can be observed from our participant demographics and recent
studies, those with DMD are surviving well into adulthood. Guidelines for those with type 2 diabetes
recommend non-pharmacological interventions such as diet and physical activity in the control of
blood glucose [52]. Physical activity is unlikely to be effective or possible in most adults with DMD,
and only a proportion of those with BMD. Nutritional management of impaired glucose tolerance,
alongside pharmacological intervention may be required to manage blood glucose levels in adults with
dystrophinopathies. In adults with BMD and DMD there are no nutritional guidelines regarding sugar
intake, nor does there appear to be glucose tolerance tests commonly incorporated in regular clinical
monitoring. Based on the observations in the present study, we strongly recommend that adults with
DMD and BMD be offered glucose tolerance assessments to determine whether further treatment may
be required related to impaired glucose tolerance. Our present data in adults also emphasises the need
to develop dietary guidelines consistent with those for individuals with type 2 diabetes.
Author Contributions: Conceptualization, C.I.M.; methodology, C.I.M., G.L.O.-P. and N.D.R.; validation, C.I.M.,
G.L.O.-P., E.L.B. and N.D.R.; formal analysis, E.L.B.; investigation, E.L.B, J.T.S.P., M.F.J. and B.T.E.; resources,
E.L.B., J.T.S.P., M.F.J. and B.T.E.; data curation, E.L.B.; writing—original draft preparation, E.L.B. and C.I.M.;
writing—review and editing, C.I.M., G.L.O.-P., E.L.B., M.F.J., B.T.E. and N.D.R.; visualization, E.L.B.; supervision,
C.I.M.; project administration, E.L.B.
Funding: This research received no external funding.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Huml, R.A. Muscular Dystrophy: A Concise Guide; Springer International Publishing: Basel, Switzerland, 2015.
2. Emery, A.E. The muscular dystrophies. Lancet 2002, 359, 687–695. [CrossRef]
3. Bushby, K.; Finkel, R.; Birnkrant, D.J.; Case, L.E.; Clemens, P.R.; Cripe, L.; Kaul, A.; Kinnett, K.; McDonald, C.;
Pandya, S.; et al. Diagnosis and management of duchenne muscular dystrophy, part 1: Diagnosis, and
pharmacological and psychosocial management. Lancet Neurol. 2010, 9, 77–93. [CrossRef]
4. Hoffman, E.P.; Brown, R.H., Jr.; Kunkel, L.M. Dystrophin: The protein product of the duchenne muscular
dystrophy locus. Cell 1987, 51, 919–928. [CrossRef]
5. Deenen, J.C.; Horlings, C.G.; Verschuuren, J.J.; Verbeek, A.L.; van Engelen, B.G. The epidemiology of
neuromuscular disorders: A comprehensive overview of the literature. J. Neuromuscul. Dis. 2015, 2, 73–85.
[PubMed]
Nutrients 2018, 10, 1947 9 of 11
6. Emery, A.E. Population frequencies of inherited neuromuscular diseases—A world survey.
Neuromuscul. Disord. 1991, 1, 19–29. [CrossRef]
7. Flanigan, K.M. Duchenne and becker muscular dystrophies. Neurol. Clin. 2014, 32, 671–688. [CrossRef]
8. Birnkrant, D.J.; Bushby, K.; Bann, C.M.; Apkon, S.D.; Blackwell, A.; Brumbaugh, D.; Case, L.E.; Clemens, P.R.;
Hadjiyannakis, S.; Pandya, S.; et al. Diagnosis and management of duchenne muscular dystrophy, part 1:
Diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management.
Lancet Neurol. 2018, 17, 251–267. [CrossRef]
9. Morse, C.I.; Smith, J.; Denny, A.; Tweedale, J.; Searle, N.D. Gastrocnemius medialis muscle architecture
and physiological cross sectional area in adult males with duchenne muscular dystrophy. J. Musculoskelet.
Neuronal. Interact. 2015, 15, 154–160.
10. Morse, C.I.; Smith, J.; Denny, A.; Tweedale, J.; Searle, N.D.; Winwood, K.; Onambele-Pearson, G.L. Bone health
measured using quantitative ultrasonography in adult males with muscular dystrophy. J. Musculoskelet.
Neuronal. Interact. 2016, 16, 339–347.
11. Jacques, M.F.; Orme, P.; Smith, J.; Morse, C.I. Resting energy expenditure in adults with becker’s muscular
dystrophy. PLoS ONE 2017, 12, e0169848. [CrossRef]
12. Løkken, N.; Hedermann, G.; Thomsen, C.; Vissing, J. Contractile properties are disrupted in becker muscular
dystrophy, but not in limb girdle type 2i. Ann. Neurol. 2016, 80, 466–471. [CrossRef] [PubMed]
13. Duboc, D.; Meune, C.; Pierre, B.; Wahbi, K.; Eymard, B.; Toutain, A.; Berard, C.; Vaksmann, G.; Weber, S.;
Becane, H.M. Perindopril preventive treatment on mortality in duchenne muscular dystrophy: 10 years’
follow-up. Am. Heart J. 2007, 154, 596–602. [CrossRef] [PubMed]
14. Simonds, A.K.; Muntoni, F.; Heather, S.; Fielding, S. Impact of nasal ventilation on survival in hypercapnic
duchenne muscular dystrophy. Thorax 1998, 53, 949–952. [CrossRef] [PubMed]
15. Moon, S.S. Low skeletal muscle mass is associated with insulin resistance, diabetes, and metabolic syndrome
in the korean population: The korea national health and nutrition examination survey (knhanes) 2009–2010.
Endocr. J. 2014, 61, 61–70. [CrossRef] [PubMed]
16. Srikanthan, P.; Karlamangla, A.S. Relative muscle mass is inversely associated with insulin resistance
and prediabetes. Findings from the third national health and nutrition examination survey. J. Clin.
Endocrinol. Metab. 2011, 96, 2898–2903. [CrossRef] [PubMed]
17. Sinacore, D.R.; Gulve, E.A. The role of skeletal muscle in glucose transport, glucose homeostasis, and insulin
resistance: Implications for physical therapy. Phys. Ther. 1993, 73, 878–891. [CrossRef] [PubMed]
18. DePirro, R.; Lauro, R.; Testa, I.; Ferretti, I.; De Martinis, C.; Dellatonio, R. Decreased insulin receptors
but normal glucose metabolism in duchenne muscular dystrophy. Science 1982, 216, 311–313. [CrossRef]
[PubMed]
19. Freidenberg, G.R.; Olefsky, J.M. Dissociation of insulin resistance and decreased insulin receptor binding in
duchenne muscular dystrophy. J. Clin. Endocrinol. Metab. 1985, 60, 320–327. [CrossRef] [PubMed]
20. Haymond, M.W.; Strobel, K.E.; DeVivo, D.C. Muscle wasting and carbohydrate homeostasis in duchenne
muscular dystrophy. Neurology 1978, 28, 1224–1231. [CrossRef] [PubMed]
21. Rodriguez-Cruz, M.; Sanchez, R.; Escobar, R.E.; Cruz-Guzman Odel, R.; Lopez-Alarcon, M.; Bernabe
Garcia, M.; Coral-Vazquez, R.; Matute, G.; Velazquez Wong, A.C. Evidence of insulin resistance and other
metabolic alterations in boys with duchenne or becker muscular dystrophy. Int. J. Endocrinol. 2015, 2015,
867273. [CrossRef] [PubMed]
22. Morse, C.I.; Bostock, E.L.; Twiss, H.M.; Kapp, L.H.; Orme, P.; Jacques, M.F. The cardiorespiratory response
and physiological determinants of the assisted 6-minute handbike cycle test in adult males with muscular
dystrophy. Muscle Nerve 2018, 58, 427–433. [CrossRef] [PubMed]
23. Shimokata, H.; Muller, D.C.; Fleg, J.L.; Sorkin, J.; Ziemba, A.W.; Andres, R. Age as independent determinant
of glucose tolerance. Diabetes 1991, 40, 44–51. [CrossRef] [PubMed]
24. World Medical, A. World medical association declaration of helsinki: Ethical principles for medical research
involving human subjects. JAMA 2013, 310, 2191–2194.
25. Reeves, S.L.; Varakamin, C.; Henry, C.J. The relationship between arm-span measurement and height with
special reference to gender and ethnicity. Eur. J. Clin. Nutr. 1996, 50, 398–400. [PubMed]
26. Menke, A.; Casagrande, S.; Geiss, L.; Cowie, C.C. Prevalence of and trends in diabetes among adults in the
united states, 1988–2012. JAMA 2015, 314, 1021–1029. [CrossRef] [PubMed]
Nutrients 2018, 10, 1947 10 of 11
27. Twig, G.; Afek, A.; Derazne, E.; Tzur, D.; Cukierman-Yaffe, T.; Gerstein, H.C.; Tirosh, A. Diabetes risk among
overweight and obese metabolically healthy young adults. Diabetes Care 2014, 37, 2989–2995. [CrossRef]
[PubMed]
28. Okasora, K.; Takaya, R.; Tokuda, M.; Fukunaga, Y.; Oguni, T.; Tanaka, H.; Konishi, K.; Tamai, H. Comparison
of bioelectrical impedance analysis and dual energy x-ray absorptiometry for assessment of body composition
in children. Pediatr. Int. 1999, 41, 121–125. [CrossRef]
29. Sun, G.; French, C.R.; Martin, G.R.; Younghusband, B.; Green, R.C.; Xie, Y.G.; Mathews, M.; Barron, J.R.;
Fitzpatrick, D.G.; Gulliver, W.; et al. Comparison of multifrequency bioelectrical impedance analysis with
dual-energy x-ray absorptiometry for assessment of percentage body fat in a large, healthy population. Am. J.
Clin. Nutr. 2005, 81, 74–78. [CrossRef]
30. Mok, E.; Letellier, G.; Cuisset, J.M.; Denjean, A.; Gottrand, F.; Hankard, R. Assessing change in body
composition in children with duchenne muscular dystrophy: Anthropometry and bioelectrical impedance
analysis versus dual-energy x-ray absorptiometry. Clin. Nutr. 2010, 29, 633–638. [CrossRef]
31. Di Iorio, B.R.; Terracciano, V.; Bellizzi, V. Bioelectrical impedance measurement: Errors and artifacts.
J. Ren. Nutr. 1999, 9, 192–197. [CrossRef]
32. Reeves, N.D.; Maganaris, C.N.; Narici, M.V. Ultrasonographic assessment of human skeletal muscle size.
Eur. J. Appl. Physiol. 2004, 91, 116–118. [CrossRef] [PubMed]
33. American Diabetes, A. (2) classification and diagnosis of diabetes. Diabetes Care 2015, 38, S8–S16. [CrossRef]
[PubMed]
34. Chilelli, N.C.; Cosma, C.; Ragazzi, E.; Burlina, S.; Zaninotto, M.; Plebani, M.; Lapolla, A. Screening with
hba1c identifies only one in two individuals with diagnosis of prediabetes at oral glucose tolerance test:
Findings in a real-world caucasian population. Acta Diabetol. 2014, 51, 875–882. [CrossRef] [PubMed]
35. Weeks, B.K.; Beck, B.R. The bpaq: A bone-specific physical activity assessment instrument. Osteoporos. Int.
2008, 19, 1567–1577. [CrossRef] [PubMed]
36. Washburn, R.A.; Zhu, W.; McAuley, E.; Frogley, M.; Figoni, S.F. The physical activity scale for individuals
with physical disabilities: Development and evaluation. Arch. Phys. Med. Rehabil. 2002, 83, 193–200.
[CrossRef] [PubMed]
37. Van der Ploeg, H.P.; Streppel, K.R.; van der Beek, A.J.; van der Woude, L.H.; Vollenbroek-Hutten, M.;
van Mechelen, W. The physical activity scale for individuals with physical disabilities: Test-retest reliability
and comparison with an accelerometer. J. Phys. Act. Health 2007, 4, 96–100. [CrossRef]
38. Son, J.W.; Lee, S.S.; Kim, S.R.; Yoo, S.J.; Cha, B.Y.; Son, H.Y.; Cho, N.H. Low muscle mass and risk of type 2
diabetes in middle-aged and older adults: Findings from the koges. Diabetologia 2017, 60, 865–872. [CrossRef]
39. Vohra, R.S.; Lott, D.; Mathur, S.; Senesac, C.; Deol, J.; Germain, S.; Bendixen, R.; Forbes, S.C.; Sweeney, H.L.;
Walter, G.A.; et al. Magnetic resonance assessment of hypertrophic and pseudo-hypertrophic changes
in lower leg muscles of boys with duchenne muscular dystrophy and their relationship to functional
measurements. PLoS ONE 2015, 10, e0128915. [CrossRef]
40. Beenakker, E.A.; de Vries, J.; Fock, J.M.; van Tol, M.; Brouwer, O.F.; Maurits, N.M.; van der Hoeven, J.H.
Quantitative assessment of calf circumference in duchenne muscular dystrophy patients. Neuromuscul. Disord.
2002, 12, 639–642. [CrossRef]
41. Forbes, S.C.; Walter, G.A.; Rooney, W.D.; Wang, D.J.; DeVos, S.; Pollaro, J.; Triplett, W.; Lott, D.J.; Willcocks, R.J.;
Senesac, C.; et al. Skeletal muscles of ambulant children with duchenne muscular dystrophy: Validation
of multicenter study of evaluation with mr imaging and mr spectroscopy. Radiology 2013, 269, 198–207.
[CrossRef]
42. Gong, Q.Y.; Phoenix, J.; Kemp, G.J.; Garcia-Finana, M.; Frostick, S.P.; Brodie, D.A.; Edwards, R.H.;
Whitehouse, G.H.; Roberts, N. Estimation of body composition in muscular dystrophy by mri and stereology.
J. Magn. Reson. Imaging 2000, 12, 467–475. [CrossRef]
43. Monforte, M.; Mercuri, E.; Laschena, F.; Ricci, E.; Tasca, G. Calf muscle involvement in becker muscular
dystrophy: When size does not matter. J. Neurol. Sci. 2014, 347, 301–304. [CrossRef] [PubMed]
44. Ryder, S.; Leadley, R.M.; Armstrong, N.; Westwood, M.; de Kock, S.; Butt, T.; Jain, M.; Kleijnen, J. The burden,
epidemiology, costs and treatment for duchenne muscular dystrophy: An evidence review. Orphanet J.
Rare Dis. 2017, 12, 79. [CrossRef]
45. Hwang, J.L.; Weiss, R.E. Steroid-induced diabetes: A clinical and molecular approach to understanding and
treatment. Diabetes Metab. Res. Rev. 2014, 30, 96–102. [CrossRef] [PubMed]
Nutrients 2018, 10, 1947 11 of 11
46. Takuya, I.; Yoshiyuki, K.; Yutaka, N.; Shigeki, K.; Michio, K. Steroid-induced diabetes mellitus and related
risk factors in patients with neurologic diseases. Pharmacotherapy 2004, 24, 508–514.
47. Burke, J.P.; Williams, K.; Gaskill, S.P.; Hazuda, H.P.; Haffner, S.M.; Stern, M.P. Rapid rise in the incidence of
type 2 diabetes from 1987 to 1996: Results from the san antonio heart study. Arch. Intern. Med. 1999, 159,
1450–1456. [CrossRef] [PubMed]
48. Harris, M.I.; Flegal, K.M.; Cowie, C.C.; Eberhardt, M.S.; Goldstein, D.E.; Little, R.R.; Wiedmeyer, H.M.;
Byrd-Holt, D.D. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in u.S.
Adults. The third national health and nutrition examination survey, 1988-1994. Diabetes Care 1998, 21,
518–524. [CrossRef]
49. King, H.; Aubert, R.E.; Herman, W.H. Global burden of diabetes, 1995–2025: Prevalence, numerical estimates,
and projections. Diabetes Care 1998, 21, 1414–1431. [CrossRef]
50. Van Dam, R.M.; Rimm, E.B.; Willett, W.C.; Stampfer, M.J.; Hu, F.B. Dietary patterns and risk for type 2
diabetes mellitus in u.S. Men. Ann. Intern. Med. 2002, 136, 201–209. [CrossRef]
51. Boehme, M.W.; Buechele, G.; Frankenhauser-Mannuss, J.; Mueller, J.; Lump, D.; Boehm, B.O.; Rothenbacher, D.
Prevalence, incidence and concomitant co-morbidities of type 2 diabetes mellitus in south western
germany—A retrospective cohort and case control study in claims data of a large statutory health insurance.
BMC Public Health 2015, 15, 855. [CrossRef]
52. Tuomilehto, J.; Lindström, J.; Eriksson, J.G.; Valle, T.T.; Hämäläinen, H.; Ilanne-Parikka, P.; Keinänen-Kiukaanniemi, S.;
Laakso, M.; Louheranta, A.; Rastas, M.; et al. Prevention of type 2 diabetes mellitus by changes in lifestyle
among subjects with impaired glucose tolerance. N. Engl. J. Med. 2001, 344, 1343–1350. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
